Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)

Advances in immune checkpoint therapy and targeted therapy have led to improvement in overall survival for patients with advanced melanoma. Single agent checkpoint PD-1 blockade and combination with BRAF/MEK targeted therapy demonstrated benefit in overall survival (OS). Superior response rates have...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Transl Med
Autors principals: Ascierto, Paolo A., Blank, Christian, Dummer, Reinhard, Ernstoff, Marc S., Ferrone, Soldano, Fox, Bernard A., Gajewski, Thomas F., Garbe, Claus, Hwu, Patrick, Kalinski, Pawel, Krogsgaard, Michelle, Lo, Roger S., Luke, Jason J., Neyns, Bart, Postow, Michael A., Quezada, Sergio A., Teng, Michele W. L., Trinchieri, Giorgio, Testori, Alessandro, Caracò, Corrado, Osman, Iman, Puzanov, Igor, Thurin, Magdalena
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Meeting Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8243582/
https://ncbi.nlm.nih.gov/pubmed/34193182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-021-02951-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars